Search results for "Apolipoprotein A1"

showing 8 items of 8 documents

The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review

2017

Cardiovascular disease (CVD) is the leading cause of death worldwide, and so the search for innovative and accurate biomarkers for guiding prevention, diagnosis, and treatment is a valuable clinical and economic endeavor. Due to a recent findings that the serum concentration of mitochondrial ATP synthase inhibitory factor 1 (IF1) is an independent prognostic factor in patients with coronary heart disease (CHD), we reviewed the role of this protein in myocardial ischemic preconditioning, its correlation to plasma high density lipoprotein (HDL), the predictive potential in patients with CHD, and its interplay with angiogenesis. IF1 has been positively correlated with plasma HDL-cholesterol, a…

0301 basic medicinemedicine.medical_specialtyClinical chemistryAngiogenesisEndocrinology Diabetes and MetabolismInhibitory factor 1Clinical BiochemistryHigh density lipoproteinCoronary DiseaseClinical nutritionDiseaseReview030204 cardiovascular system & hematologyBioinformaticsMitochondrial Proteins03 medical and health scienceschemistry.chemical_compoundAngiogenesis; Cardiovascular disease; High density lipoprotein; Inhibitory factor 10302 clinical medicineEndocrinologyHigh-density lipoproteinInternal medicineMedicineHumansCause of deathBiochemistry medicalbiologybusiness.industryBiochemistry (medical)ProteinsCardiovascular diseaseMitochondria030104 developmental biologyEndocrinologychemistrybiology.proteinIschemic preconditioningApolipoprotein A1AngiogenesisbusinessLipids in Health and Disease
researchProduct

Associations of Aerobic Fitness and Maximal Muscular Strength With Metabolites in Young Men

2019

This cross-sectional study of young Finnish men examines the associations of aerobic fitness and muscular strength with metabolome measures that are associated with cardiometabolic risks.

AdultMalePhysical fitnessCardiologyPhysiologyPhysical strengthBody fat percentageLipoprotein particlechemistry.chemical_compoundYoung AdultRisk FactorsMedicineAerobic exerciseHumansMuscle Strengthmetabolinen oireyhtymäExerciseFinlandOriginal Investigationaerobic fitnessmaximal muscular strengthTriglyceridebiologybusiness.industryResearchVO2 maxGeneral MedicineMiddle AgedOnline OnlyCross-Sectional StudiesMetabolismMilitary PersonnelchemistryPhysical Fitnessbiology.proteinsydän- ja verisuonitauditMetabolomeApolipoprotein A1aerobinen suorituskykybusinesslihaskuntoBiomarkerscardiometabolic disease riskJAMA Network Open
researchProduct

Effect of alpha-linolenic acid in combination with the flavonol quercetin on markers of cardiovascular disease risk in healthy, non-obese adults: A r…

2019

Abstract Objectives Alpha-linolenic acid (ALA) and quercetin are characteristic compounds in plant-based diets. Cardioprotective effects have been described for both substances, although a possible benefit of combining ALA and quercetin has not, to our knowledge, been evaluated yet. The aim of this study was to investigate the potential independent and additive effects of ALA and quercetin on blood pressure (BP) and lipid and glucose metabolism, as well as on biomarkers of inflammation, oxidative stress, and antioxidant status in healthy, non-obese men and women. Another aim was to examine whether chronic supplementation of supranutritional doses of quercetin would result in an accumulation…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismchemistry.chemical_compoundYoung AdultHigh-density lipoproteinDouble-Blind MethodRisk FactorsInternal medicinemedicineHumansheterocyclic compoundsIsorhamnetinNutrition and DieteticsCross-Over Studiesbiologyalpha-Linolenic acidCholesterolbusiness.industryalpha-Linolenic AcidCrossover studyEndocrinologychemistryCardiovascular DiseasesDietary Supplementsbiology.proteinApolipoprotein A1FemaleQuercetinQuercetinbusinessBiomarkersLipoproteinNutrition (Burbank, Los Angeles County, Calif.)
researchProduct

Evaluation of cardiovascular risk and oxidative stress parameters in hypercholesterolemic subjects on a standard healthy diet including low-fat milk …

2010

A healthy diet and plant sterols (PS) are recommended for reducing low-density lipoprotein (LDL) cholesterol and, subsequently, the risk of premature cardiovascular disease PS mediate a decrease in fat-soluble vitamin concentration, which can lead to a general impairment of antioxidative defenses and an increase in oxidative stress. Thus, we evaluated the effects of a healthy diet, including PS-enriched low-fat milk, on cardiovascular risk and oxidative stress parameters in hypercholesterolemic subjects. This was a randomized parallel trial employing 40 subjects and consisting of two 3-month intervention phases. After 3 months on a standard healthy diet, subjects were divided into two inter…

AdultVitaminmedicine.medical_specialtyApolipoprotein BEndocrinology Diabetes and MetabolismHypercholesterolemiaClinical Biochemistrymedicine.disease_causeBiochemistrychemistry.chemical_compoundInternal medicinemedicineAnimalsHumansMolecular BiologyAgedNutrition and Dieteticsbiologymedicine.diagnostic_testCholesterolPhytosterolsMiddle AgedOxidative StressMilkEndocrinologychemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Apolipoprotein A1CryptoxanthinLipid profileOxidative stressLipoproteinThe Journal of Nutritional Biochemistry
researchProduct

Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution

1994

Recently waist/hip ratio (WHR), a marker of body fat distribution, has been described as a risk factor for cardiovascular disease (CVD). The aim of the present study was to evaluate the influence of body fat distribution on metabolic, haemostatic and haemorheological pattern in premenopausal obese women with different WHR. Fourty premenopausal obese women were subdivided into two groups, matched for age and body mass index (BMI): 20 women with abdominal obesity (WHR = 0.94 +/- 0.02) and 20 women with peripheral obesity (WHR = 0.77 +/- 0.03). Twenty nonobese women were recruited as control group. The abdominal obesity group had significantly higher blood glucose, triglycerides, total cholest…

Adultmedicine.medical_specialtymedicine.medical_treatmentFibrinogenchemistry.chemical_compoundHigh-density lipoproteinRisk FactorsInternal medicineFibrinolysismedicineHumansObesityBlood CoagulationAbdominal obesitybiologybusiness.industryCholesterolFibrinolysisFibrinogenBlood ProteinsHematologyFactor VIIBlood Viscositymedicine.diseaseLipidsObesityEndocrinologyHematocritPremenopausechemistryCardiovascular DiseasesHemorheologybiology.proteinBody ConstitutionFemaleApolipoprotein A1medicine.symptombusinessBody mass indexmedicine.drugThrombosis Research
researchProduct

Temperature‐Responsive Nanoparticles Enable Specific Binding of Apolipoproteins from Human Plasma

2021

Apolipoproteins are an important class of proteins because they provide a so-called stealth effect to nanoparticles. The stealth effect on nanocarriers leads to a reduced unspecific uptake into immune cells and thereby to a prolonged blood circulation time. Herein, a novel strategy to bind apolipoproteins specifically on nanoparticles by adjusting the temperature during their incubation in human plasma is presented. This specific binding, in turn, allows a control of the stealth behavior of the nanoparticles. Nanoparticles with a well-defined poly(N-isopropylacrylamide) shell are prepared, displaying a reversible change of hydrophobicity at a temperature around 32 °C. It is shown by label-f…

Apolipoprotein EbiologyChemistryTemperatureNanoparticleProtein CoronaGeneral ChemistryPlasma protein bindingbiology.organism_classificationBiomaterialsHeLaApolipoproteinsBiophysicsbiology.proteinHumansNanoparticlesSurface modificationProtein CoronaGeneral Materials ScienceApolipoprotein A1NanocarriersHeLa CellsBiotechnologySmall
researchProduct

Elevated levels of lipoprotein (a) in patients suffering from myocardial infarction with carotid atherosclerotic lesions.

1999

The aim of the present study was to evaluate metabolic, coagulation and fibrinolytic parameters in 45 patients [31 men, 14 women, aged 56.5 +/- 3.5 years (mean +/- SD)] who had suffered myocardial infarction more than 6 months earlier, with or without carotid atherosclerotic lesions. After the extracranial carotid arteries had been evaluated using a B-mode Duplex scanning system, patients were subdivided into two groups: group 1 (n = 20) with carotid plaques or measurable intima-media thickness; and group 2 (n = 25) without carotid plaques or measurable intima-media thickness. Twenty-two age- and sex-matched subjects were recruited as controls (group 3). Groups 1 and 2 displayed significant…

Carotid Artery DiseasesMalemedicine.medical_specialtyArteriosclerosismedicine.medical_treatmentLipoproteinsMyocardial InfarctionFibrinogenBody Mass IndexRisk FactorsInternal medicineFibrinolysismedicineHumansMyocardial infarctionBlood CoagulationTriglyceridesbiologybusiness.industryFibrinolysisHematologyGeneral MedicineLipoprotein(a)Middle Agedmedicine.diseaseEndocrinologyApolipoproteinsCholesterolbiology.proteinCardiologyApolipoprotein A1FemalebusinessPlasminogen activatorProtein CBiomarkersLipoproteinmedicine.drugLipoprotein(a)Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Apolipoprotein A1 in Cerebrospinal Fluid Is Insufficient to Distinguish Alzheimer's Disease from Other Dementias in a Naturalistic, Clinical Setting.

2020

Apolipoprotein A1 (ApoA1) is the major protein component of the high-density lipoprotein and involved in cholesterol transport. Disruption of cholesterol homeostasis has been identified as a contributing factor for Alzheimer's disease (AD). Moreover, polymorphisms of ApoA1 have been associated with higher risk of disease onset and cognitive decline. Therefore, ApoA1 has been suggested as a biomarker in AD. Here, we tested a small cohort of AD and non-AD dementia patients and measured levels of ApoA1 in cerebrospinal fluid. Our results indicate that ApoA1 might not be applicable to distinguish AD from other forms of dementia.

Short CommunicationDiseasecerebrospinal fluidchemistry.chemical_compoundmedicineDementiaCognitive declinebiologyCholesterolbusiness.industryGeneral Neurosciencemedicine.diseasePsychiatry and Mental healthClinical PsychologychemistryCohortImmunologybiology.proteinBiomarker (medicine)biomarkerApolipoprotein A1lipids (amino acids peptides and proteins)Apolipoprotein A1Geriatrics and GerontologybusinessAlzheimer’s diseaseLipoproteindementiaJournal of Alzheimer's disease reports
researchProduct